Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
Open Access
- 1 March 2016
- journal article
- review article
- Published by Elsevier BV in Acta Pharmaceutica Sinica. B
- Vol. 6 (2), 101-105
- https://doi.org/10.1016/j.apsb.2016.01.002
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (26462076)
This publication has 48 references indexed in Scilit:
- Prognostic Impact of Hyaluronan and Its Regulators in Pancreatic Ductal AdenocarcinomaPLOS ONE, 2013
- Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancerBMC Cancer, 2013
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancerGut, 2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Targeting the Tumor Microenvironment in Cancer: Why Hyaluronidase Deserves a Second LookCancer Discovery, 2011
- Targeting Hyaluronidase for Cancer Therapy: Antitumor Activity of Sulfated Hyaluronic Acid in Prostate Cancer CellsCancer Research, 2011
- Hyaluronan–CD44 interactions as potential targets for cancer therapyThe FEBS Journal, 2011
- Pancreatic CancerThe New England Journal of Medicine, 2010
- Hyaluronan-CD44 Interactions in Cancer: Paradoxes and PossibilitiesClinical Cancer Research, 2009
- Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL)Biochemical and Biophysical Research Communications, 2006